NASDAQ:BNTX BioNTech (BNTX) Stock Price, News & Analysis $96.06 -2.60 (-2.64%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$97.00 +0.94 (+0.98%) As of 09/18/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About BioNTech Stock (NASDAQ:BNTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BioNTech alerts:Sign Up Key Stats Today's Range$95.71▼$99.2550-Day Range$89.33▼$116.5752-Week Range$79.52▼$124.00Volume1.20 million shsAverage Volume1.17 million shsMarket Capitalization$24.29 billionP/E RatioN/ADividend YieldN/APrice Target$126.00Consensus RatingModerate Buy Company Overview BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators. The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors. BioNTech was founded in 2008 and is headquartered in Mainz, Germany. Through research, manufacturing and commercial activities, it serves markets in Europe, North America and other international regions. The company was co-founded by Chief Executive Officer Uğur Şahin, Chief Medical Officer Özlem Türeci and Christoph Huber.AI Generated. May Contain Errors. Read More BioNTech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks87th Percentile Overall ScoreBNTX MarketRank™: BioNTech scored higher than 87% of companies evaluated by MarketBeat, and ranked 90th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingBioNTech has received a consensus rating of Moderate Buy. The company's average rating score is 2.68, and is based on 1 strong buy rating, 12 buy ratings, 5 hold ratings, and 1 sell rating.Upside PotentialBioNTech has a consensus price target of $126.00, representing about 31.2% upside from its current price of $96.06.Amount of Analyst CoverageBioNTech has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BioNTech's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BioNTech are expected to grow in the coming year, from ($6.37) to ($5.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioNTech is -12.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioNTech is -12.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioNTech has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about BioNTech's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.13% of the float of BioNTech has been sold short.Short Interest Ratio / Days to CoverBioNTech has a short interest ratio ("days to cover") of 0.98, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioNTech has recently decreased by 8.16%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioNTech does not currently pay a dividend.Dividend GrowthBioNTech does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.14 News SentimentBioNTech has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 29 news articles for BioNTech this week, compared to 7 articles on an average week.Search Interest16 people have searched for BNTX on MarketBeat in the last 30 days. This is an increase of 78% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added BioNTech to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, BioNTech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $36,454,275.00 in company stock.Percentage Held by Insiders19.20% of the stock of BioNTech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions15.52% of the stock of BioNTech is held by institutions.Read more about BioNTech's insider trading history. Receive BNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BNTX Stock News HeadlinesBioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 30,000 Shares of Stock21 minutes ago | insidertrades.comAnalysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL) and BioNTech SE (BNTX)September 18 at 7:56 AM | theglobeandmail.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.September 19 at 1:00 AM | InvestorPlace (Ad)Is BioNTech (BNTX) Too Pricey for Its Current Sales Base?September 17 at 9:56 AM | finance.yahoo.comModerna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge HigherSeptember 17 at 9:50 AM | 247wallst.comBioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 15,000 SharesSeptember 17 at 6:37 AM | insidertrades.comBioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 41,000 Shares of StockSeptember 15, 2026 | insidertrades.comUgur Sahin Sells 20,500 Shares of BioNTech (NASDAQ:BNTX) StockSeptember 12, 2026 | insidertrades.comSee More Headlines BNTX Stock Analysis - Frequently Asked Questions How have BNTX shares performed this year? BioNTech's stock was trading at $95.20 at the start of the year. Since then, BNTX shares have increased by 0.9% and is now trading at $96.06. How were BioNTech's earnings last quarter? BioNTech SE Sponsored ADR (NASDAQ:BNTX) posted its earnings results on Tuesday, August, 4th. The company reported ($2.53) earnings per share for the quarter, missing the consensus estimate of ($2.40) by $0.14. The business's quarterly revenue was down 59.5% compared to the same quarter last year. Read the conference call transcript. How will BioNTech's stock buyback program work? BioNTech's board initiated a share repurchase program on Thursday, May 7th 2026, which authorizes the company to repurchase $1,000,000,000 in outstanding shares, according to EventVestor. This means that the company could purchase up to 4.2% of its stock through open market purchases. Stock buyback programs are typically a sign that the company's management believes its stock is undervalued. Does BioNTech have any subsidiaries? BioNTech subsidiaries include Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, and more. When did BioNTech IPO? BioNTech (BNTX) raised $155 million in an initial public offering on Thursday, October 10th 2019. The company issued 10,000,000 shares at $15.00-$16.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink acted as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers. Who are BioNTech's major shareholders? Top institutional investors of BioNTech include Flossbach Von Storch SE (0.88%), Assenagon Asset Management S.A. (0.17%), Wellington Management Group LLP (0.05%) and Carmignac Gestion (0.03%). Insiders that own company stock include Ugur Sahin and Sierk Poetting. View institutional ownership trends. How do I buy shares of BioNTech? Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioNTech own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioNTech investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AUO (AUOTY) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/04/2026Today9/18/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 BNTX's financial health is in the Green zone, according to TradeSmith. BNTX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BNTX CIK1776985 Webwww.biontech.com Phone49-61-31908-40Fax49-6131-908-4390Employees7,807Year Founded2008Price Target and Rating Average Price Target for BioNTech$126.00 High Price Target$155.00 Low Price Target$94.00 Potential Upside/Downside+31.2%Consensus RatingModerate Buy Rating Score (0-4)2.68 Research Coverage19 Analysts Profitability EPS (Trailing Twelve Months)($7.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.29 billion Net Margins-63.54% Pretax Margin-62.27% Return on Equity-6.86% Return on Assets-6.00% Debt Debt-to-Equity Ratio0.01 Current Ratio7.85 Quick Ratio7.80 Sales & Book Value Annual Sales$3.25 billion Price / Sales7.48 Cash Flow$1.30 per share Price / Cash Flow73.90 Book Value$96.59 per share Price / Book0.99Miscellaneous Outstanding Shares252,880,000Free Float204,330,000Market Cap$24.29 billion OptionableOptionable Beta1.29 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:BNTX) was last updated on 9/19/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNTech SE Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share BioNTech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
